In addition, NCT02571036 is a phase 1 trial that will evaluate DCC-2618 (ripretinib, a TKI designed to inhibit specifically KIT and PDGFR-A kinases) in patients with advanced cancers, and the trial NCT04771520 is currently recruiting patients with advanced or metastatic solid tumors with c-KIT or PDGFR-A mutations to receive avapritinib (BLU-285). The gene discussed is PDGFRA; the disease is cancer.